Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
СпутникиРНSpaceXРоскосмосNASANew indication concerns combination with pembrolizumab, as neoadjuvant and adjuvant treatment in patients with resectable MIBC who are ineligible for cisplatin
Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.
ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH
© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan | 0 | 5 | 10-07-2026 |
| 2 | EMA recommends extension of therapeutic indications for sacituzumab govitecan | 0 | 11.1 | 18-09-2026 |
| 3 | EMA Recommends Extension of Therapeutic Indications for Trastuzumab Deruxtecan | 0 | 5 | 26-06-2026 |
| 4 | EMA Recommends Extension of Therapeutic Indications for Encorafenib | 0 | 5 | 03-07-2026 |
| 5 | EMA Recommends Extension of Therapeutic Indications for Cetuximab | 0 | 11.3 | 14-08-2026 |
| 6 | EMA Recommends Extension of Therapeutic Indications for Epcoritamab | 0 | 8.04 | 24-07-2026 |
| 7 | FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer | 5 | 5 | 08-07-2026 |
| 8 | New targeted therapy shows promising early results in advanced pancreatic cancer | 2 | 7 | 05-07-2026 |
| 9 | FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC | 5 | 7 | 24-06-2026 |
| 10 | New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer | 5 | 7 | 02-07-2026 |